Completed NA INTERVENTIONAL 1-arm NCT00818298

24-Hour Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study

Sponsor: Centre for Addiction and Mental Health

Conditions Schizoaffective Disorder Schizophrenia

Interventions ziprazidone

Updated 5 times since 2017 Last updated: Jul 6, 2012 Started: Jan 31, 2009 Primary completion: Jan 31, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Schizoaffective Disorder and Schizophrenia and is currently completed. Centre for Addiction and Mental Health leads this study, which shows 5 recorded versions since 2009 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre for Addiction and Mental Health
Pfizer

Data source: Centre for Addiction and Mental Health

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada